Challenges in the development of vaccines against COVID-19
Main Article Content
Keywords
SARS Virus, Immunogenicity, Vaccine, Immunity
Abstract
To face the urgent need of a COVID-19 vaccine, currently more than 90 candidates are being developed using different strategies, such as inactivated or attenuated SARS-CoV-2 virus, viral vectors expressing antigens of this virus, nucleic acids or purified viral proteins. These vaccines are in preclinical development and at least six of them have already been injected into volunteers in safety clinical trials. However, the characteristics of the protective immue responses are still unknown, therefore there is not evidence to indicate that these vaccines will induce protection and if this will be long-lasting. The development of SARS-CoV-2 vaccines is vital, nevertheless, is also important to unveil the characteristics of the protective immune resposes to guide the design of a vaccine that generates a long-lasting protection against COVID-19.
References
1. Amanat F, Krammer F. SARS-CoV-2 vaccines:status report. Immunity. 2020;4:583-9. Disponible en:https://www.sciencedirect.com/science/article/pii/S1074761320301205
2. Thanh Le T, Andreadakis Z, Kumar A, Gómez-Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-6. Disponible en:http://www.nature.com/articles/d41573-020-00073-5
3. Callaway E. The race for coronavirus vaccines:a graphical guide. Nature. 2020;580(7805):576-7. Disponible en:http://www.nature.com/articles/d41586-020-01221-y
4. Diaz-Granados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults:Safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013;31(6):861-6. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/S0264410X1201780X
5. Tsai TF. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother. 2013;45(2):159-74. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780956
6. Albrich WC, Madhi SA, Lafond KE, Klugman KP. Herd immunity after pneumococcal conjugate vaccination. Lancet. 2007;370(9583):218-9.
7. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020;1-5. Disponible en:https://www.nejm.org/doi/10.1056/NEJMp2005630?url_ver=Z39.88-2003 and rfr_id=ori:rid:crossref.org and rfr_dat=cr_pub%20%200pubmed
8. Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, et al. T Cell Responses to Whole SARS Coronavirus in Humans. J Immunol. 2008;181(8):5490-500.
9. Liu W, Fontanet A, Zhang P, Zhan L, Xin Z, Baril L, et al. Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome. J Infect Dis. 2006;193(6):792-5.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.